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Abstract
Background: CUG-BP and ETR-3-like factor (CELF) proteins regulate tissue- and developmental stage-specific alternative
splicing in striated muscle. We previously demonstrated that heart muscle-specific expression of a nuclear dominant
negative CELF protein in transgenic mice (MHC-CELFD) effectively disrupts endogenous CELF activity in the heart in vivo,
resulting in impaired cardiac function. In this study, transgenic mice that express the dominant negative protein under a
skeletal muscle-specific promoter (Myo-CELFD) were generated to investigate the role of CELF-mediated alternative splicing
programs in normal skeletal muscle.
Methodology/Principal Findings: Myo-CELFD mice exhibit modest changes in CELF-mediated alternative splicing in
skeletal muscle, accompanied by a reduction of endomysial and perimysial spaces, an increase in fiber size variability, and an
increase in slow twitch muscle fibers. Weight gain and mean body weight, total number of muscle fibers, and overall muscle
strength were not affected.
Conclusions/Significance: Although these findings demonstrate that CELF activity contributes to the normal alternative
splicing of a subset of muscle transcripts in vivo, the mildness of the effects in Myo-CELFD muscles compared to those in
MHC-CELFD hearts suggests CELF activity may be less determinative for alternative splicing in skeletal muscle than in heart
muscle. Nonetheless, even these small changes in CELF-mediated splicing regulation were sufficient to alter muscle
organization and muscle fiber properties affected in myotonic dystrophy. This lends further evidence to the hypothesis that
dysregulation of CELF-mediated alternative splicing programs may be responsible for the disruption of these properties
during muscle pathogenesis.
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Introduction
Pre-mRNA alternative splicing is a common mechanism for
generating transcript and protein diversity. It is estimated that
more than 90% of human genes produce alternatively spliced
transcripts, with the majority of these exhibiting tissue-specific
regulation [1,2]. Two members of the CUG-BP and ETR-3-like
factor (CELF) family, CELF1 (also known as CUG-BP1) and
CELF2 (also known as CUG-BP2 or ETR-3), are expressed in
heart and skeletal muscle, where they have been shown to be key
regulators of tissue- and developmental stage-specific alternative
splicing [3–6]. CELF1 and CELF2 protein levels are normally
down-regulated in vertebrate heart and skeletal muscle shortly
after birth [4,6]. This regulation occurs post-transcriptionally,
involving destabilizing modifications of the CELF1 protein and
microRNA-mediated repression of translation of CELF1 and
CELF2 transcripts [7,8]. In the heart, a recent study found that
nearly half of transcripts that undergo fetal-to-adult alternative
splicing transitions in mice respond to over-expression of CELF1,
suggesting that the level of CELF activity is determinative for
alternative splicing of these transcripts in heart [4]. CELF proteins
have also been implicated in regulating fetal versus adult splicing
patterns of some skeletal muscle transcripts [9,10].
The postnatal down-regulation of CELF proteins is critical, as
too much CELF activity in mature heart and skeletal muscle is
pathogenic. In patients with myotonic dystrophy type 1 (DM1), an
adult-onset form of muscular dystrophy caused by the expression
of mutant transcripts from the DMPK gene containing expanded
CUG repeats [11–13], CELF1 is aberrantly up-regulated in the
heart and skeletal muscles [10,14]. CELF targets in these tissues
exhibit fetal splicing patterns, and developmental stage-inappro-
priate transcripts have been directly implicated in disease
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heart and skeletal muscle in transgenic mice following induction of
expanded CUG repeat RNA expression [16,17]. The expression
of expanded CUG repeat RNAs or over-expression of CELF1 in
heart and skeletal muscle recapitulate many of the aberrant
alternative splicing patterns observed in DM1 patient tissues, as
well as other features of DM1 pathogenesis [16–20].
Too little CELF activity can also be pathogenic. We previously
demonstrated that targeted repression of CELF activity in the
postnatal mouse heart by expression of a nuclear dominant
negative CELF protein (NLSCELFD) under the control of the
cardiac muscle-specific a-myosin heavy chain promoter (MHC-
CELFD) leads to not only changes in alternative splicing of target
transcripts, but also cardiac hypertrophy, chamber dilation, severe
cardiac dysfunction, and premature death [21,22]. These results
indicate that the persistence of some CELF activity in postnatal
heart muscle is critical for the maintenance of developmental
stage-appropriate alternative splicing and healthy cardiac function.
In this study, we use a similar dominant negative approach to
explore the role of CELF-mediated alternative splicing regulation
in normal skeletal muscle. Although previous studies have shown
that over-expression of CELF1 in skeletal muscle is sufficient to
disrupt alternative splicing and muscle phenotype [18,20], this is
the first study to test whether CELF activity is normally required in
skeletal muscle by specifically repressing CELF activity. The
dominant negative approach has several advantages over a gene
knockout approach. First, dominant negative expression can be
easily targeted to a specific tissue using a tissue-specific promoter
without the need to use a bitransgenic Cre-lox system. Second, the
dominant negative protein will simultaneously inhibit the activities
of all CELF proteins in that tissue, in this case CELF1 and CELF2.
And third, the dominant negative protein contains a strong
nuclear localization signal, so its repression should be limited to
the nucleus where alternative splicing takes place, leaving any
cytoplasmic functions of the CELF proteins unperturbed. Here we
report that skeletal muscle-specific expression of NLSCELFD
under control of the myogenin promoter (Myo-CELFD) leads to
modest changes in alternative splicing in the muscles of some, but
not all, CELF targets previously identified in the heart. These
splicing changes are accompanied by changes in endomysial and
perimysial spacing, increased variation in muscle fiber size, and
switching of muscle fiber subtypes. Body weight, fiber number,
and overall muscle strength were not impaired. The mildness of
the Myo-CELFD skeletal muscle phenotype is in stark contrast to
the strong phenotype observed in the hearts of MHC-CELFD
mice, in which both alternative splicing and cardiac function are
significantly disrupted by expression of NLSCELFD [21,22].
These data suggest that while CELF-mediated alternative splicing
regulatory programs participate in the establishment and/or
maintenance of skeletal muscle organization and fiber properties,
CELF activity may be less determinative for alternative splicing in
skeletal muscle than in heart.
Results
Transgenic lines of Myo-CELFD mice were generated that
express different levels of dominant negative protein
A truncated CELF protein, CELFD, exhibits dominant negative
activity as defined by several criteria: (1) alone it has no effect on
alternative splicing when expressed in cells lacking detectable
levels of endogenous CELF proteins, (2) it inhibits changes in
alternative splicing induced by wild type CELF proteins when co-
expressed, and (3) it has no effect on non-CELF mediated
alternative splicing [3]. A modified form of this protein,
NLSCELFD, retains its dominant negative activity and is
restricted to the nucleus [21]. Heart muscle-specific expression
of NLSCELFD in MHC-CELFD mice has been shown to
specifically disrupt cardiac CELF-mediated alternative splicing in
vivo and leads to cardiomyopathy, severe cardiac dysfunction, and
premature death [21,22]. Cardiac hypertrophy, survival, and
alternative splicing of CELF targets were all rescued by crossing
MHC-CELFD mice to mice over-expressing CELF1 in the heart,
indicating that both the molecular and gross phenotypes can be
attributed to loss of CELF activity [21]. To create mice that
express this nuclear dominant negative protein specifically in
skeletal muscle, a transgene was created (Myo-CELFD; Figure 1A)
in which expression of NLSCELFD is driven by the mouse
myogenin promoter. The myogenin promoter was chosen because
it drives expression specifically in cells of the skeletal muscle
lineage, beginning prior to terminal differentiation and continuing
into adulthood [23].
Several transgenic founders with germ line transmission were
obtained. First generation offspring were screened for expression
of the NLSCELFD protein in skeletal muscle by western blotting,
and three lines (Myo-CELFD-360, -370, and –396) with different
levels of detectable transgene expression were obtained. Trans-
genic animals from the lowest-expressing line, Myo-CELFD-360,
became severely obese at a young age. As obesity was not observed
in any other line despite much higher levels of NLSCELFD
expression, this can likely be attributed to the integration site of the
transgene. Given the confounding effects that severe obesity could
have on muscle health and function, the Myo-CELFD-360 line
was culled without further analysis. Thus, only the highest- and
mid-expressing lines, Myo-CELFD-370 and -396, respectively
(Figure 1B), were selected for further study.
The initial screen for transgene expression was conducted on
pectoral muscle samples. The myogenin promoter should drive
transgene expression in late myogenic precursors and differenti-
ated skeletal muscles throughout the body, but not in non-skeletal
muscle tissues [23,24]. To confirm this expression pattern for the
Myo-CELFD transgene, several other tissues were examined by
western blot. NLSCELFD protein expression was not detected in
the heart (cardiac muscle), stomach (smooth muscle), or liver (non-
muscle) tissues of Myo-CELFD mice (Figure 1B). NLSCELFD
protein expression was strongly detected in shoulder (trapezius),
lower forelimb (extensor), diaphragm, and neck muscles in both
Myo-CELFD-370 and -396 lines (Figure 1C and data not shown).
To quantify the difference in expression levels between Myo-
CELFD lines, semi-quantitative RT-PCR was performed on
RNAs from these same skeletal muscle tissues (Figure 1D). While
no NLSCELFD transcripts were detected in wild type skeletal
muscles, NLSCELFD transcripts were detected in all skeletal
muscles evaluated for both Myo-CELFD lines, with an average of
7.961.7 fold higher expression in Myo-CELFD-370 compared to
Myo-CELFD-396 muscles. No NLSCELFD transcripts were
detected in Myo-CELFD hearts.
CELF-mediated alternative splicing is modestly disrupted
in Myo-CELFD muscle
The majority of CELF targets identified to date were found in
the developing heart [4,21]. Few CELF targets have been
identified and characterized in skeletal muscle. Alternative exons
6b and 7a of the skeletal muscle-specific chloride channel ClC-1
are aberrantly included in DM1 skeletal muscle where CELF1
levels are elevated [9], but are 100% skipped in normal muscle
and do not respond to further loss of CELF activity in Myo-
CELFD mice (data not shown). Therefore, to confirm that the
alternative splicing activity of the CELF family is disrupted in
CELF Activity Regulates Muscle Fiber Properties
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previously identified as targets of CELF regulation in the heart
[4,21] were compared in pectoral muscles from sex- and age-
matched wild type and transgenic mice (Figure 2 and Table 1). Of
the twelve known targets tested, two demonstrated significant
differences in exon inclusion between wild type and transgenic
siblings: H2afy mutually exclusive exons 6 and 7 and Capzb exon
8 (Figure 2A, B). In both cases, the direction of change that was
observed was opposite to that seen in the hearts of mice over-
expressing CELF1 [4], which is consistent with a loss of CELF
activity in Myo-CELFD muscle. There was also a trend toward
decreased inclusion of C10orf97 exon 5 in Myo-CELFD pectoral
muscle (Figure 2C), which is likewise opposite of the pattern seen
in CELF1-over-expressing mice [4]. Although the decrease in
inclusion did not quite reach statistical significance for C10orf97
exon 5 in pectoral muscle, a significant decrease was found in
thigh muscles from the same mice (41.461.8% in wild type versus
32.563.7% inclusion in Myo-CELFD-370 mice, P=0.01). Nine
other previously identified cardiac targets showed no significant
change in alternative splicing in Myo-CELFD-370 muscle
(Table 1). It should be noted that two of these that were predicted
to exhibit increases in exon inclusion based on patterns observed
in the heart [4,21], Mfn2 exon 3 and Bin 1 exon 10, already had
baseline levels of inclusion close to 100% allowing no room for an
additional shift. In addition to the previously identified CELF
targets, we examined the alternative splicing of Nrap exon 12, a
transcript identified as a novel putative target in another ongoing
study in the lab. Although Nrap exon 12 was not previously
described as a target of the CELF proteins, its inclusion is reduced
in DM1 muscle [25], which has elevated CELF1 protein levels
[10]. We found that Nrap exon 12 inclusion is elevated in Myo-
CELFD muscle (Figure 2D). Taken together, these data suggest
that CELF proteins negatively regulate Nrap exon 12 inclusion.
Myo-CELFD transgenic mice exhibit changes in muscle
organization and fiber size
Hemizygous transgenic animals from both the higher-express-
ing Myo-CELFD-370 and lower-expressing Myo-CELFD-396
lines were obtained at the expected Mendelian frequency, survive
to maturity, and live normal life spans. No significant differences in
mean body weight were observed for either males or females from
the Myo-CELFD-370 line when compared to sex-matched wild
type littermates over a sixteen-week time course, suggesting that
there are no gross changes in overall muscle mass or body morph
(Figure S1). Myo-CELFD transgenic mice also exhibit no obvious
impairment in mobility or gait.
To more closely examine the skeletal muscle of Myo-CELFD
mice, we performed histological analysis on transverse cross-
sections of limbs from adult transgenic mice and their wild type
littermates. Although there were no apparent deficiencies in the
Figure 1. Myo-CELFD transgenic mice express the nuclear dominant negative CELF protein in skeletal muscles. (A) The Myo-CELFD
transgene contains NLSCELFD behind the mouse myogenin promoter. (B) Expression of NLSCELFD protein in skeletal muscle, but not heart, stomach
(stom.), or liver, was confirmed in total protein lysates from tissues of Myo-CELFD mice by western blot using an antibody against the N-terminal
Xpress epitope tag. Equivalent loading was confirmed by Ponceau S staining. Intervening lanes with samples from non-expressing lines were excised
from the skeletal muscle blot. (C) Expression of NLSCELFD protein in a variety of Myo-CELFD skeletal muscles was confirmed by western blot using an
antibody against the N-terminal Xpress epitope tag. Protein loading and integrity was confirmed by Ponceau S staining. (D) Expression levels of
NLSCELFD were compared between Myo-CELFD lines by semi-quantitative RT-PCR. Lack of NLSCELFD transcripts in the Myo-CELFD heart (Myo) was
confirmed; RNA from the heart of an MHC-CELFD-10 mouse (MHC), in which NLSCELFD is highly expressed in cardiac muscle, was used as a positive
control.
doi:10.1371/journal.pone.0019274.g001
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endomysial and perimysial spaces were considerably reduced in
the Myo-CELFD-370 mice (Figure 3A). Similar differences were
observed in sections from the forelimb and upper hind limb (data
not shown). To quantify the extent of the reduction in interstitial
spacing, the interstitial area was measured in four different large
muscle groups in sections of lower hind limbs from two age- and
sex-matched pairs of Myo-CELFD-370 and wild type mice. While
nearly one third of the total muscle area was interstitial space in
wild type muscles (32.8±3.6% of the total area), interstitial spacing
was significantly reduced in Myo-CELFD-370 muscles (21.6±
7.4%, P=0.01). Although there appeared to be a slight reduction
in the interstitial spaces in portions of cross-sections from Myo-
CELFD-396 limbs, the differences were far less pronounced and
less consistent than in the higher-expressing Myo-CELFD-370 line
(data not shown); comparison of matched fields of lower hind limb
sections from Myo-CELFD-396 transgenic and wild type litter-
mates revealed no significant difference in total interstitial area. It
should be noted that lymphatic masses were also observed in some
cross-sections from the upper limbs of Myo-CELFD-370 but not
wild type mice; these are likely to be extensions of the auxiliary
lymph nodes. Although this could be indicative of cancerous
growth of lymphatic tissues (perhaps due to an integration site
effect in this line), there is no discernable effect on the health or
lifespan of Myo-CELFD-370 mice.
Higher magnification of the limb muscles reveals changes in
muscle fiber size in the Myo-CELFD mice (Figure 3B-E). Although
the muscle fibers within a region are roughly similar in size in wild
type mice (Figure 3B, D), muscle fiber size is highly variable in
Myo-CELFD-370 mice, ranging from very small to very large
(Figure 3C). To quantify differences in fiber size, the areas of
individual fibers were measured in several fields from matched
regions of muscle in hind limb sections from wild type and Myo-
CELFD-370 mice. Although the average fiber area did not differ
between wild type and transgenic mice (719.7±10.9 mm
2,
n=1251 fibers for wild type versus 707.7±11.7 mm
2, n=1719
fibers for Myo-CELFD-370, P=0.22), the variance, which is a
measure of the variability of the data, was significantly different
(P,0.0001). Whereas most fibers tend to cluster within a size
range close to the mean in wild type mice, fiber size is more
broadly distributed in Myo-CELFD-370 mice, with a larger
percentage of fibers falling at the ends of the spectrum (Figure 3F).
Differences were particularly pronounced at the extreme end of
the range; the maximum fiber size measured in Myo-CELFD-370
muscle was nearly twice that of the maximum fiber size in wild
type (4927 mm
2 versus 2593 mm
2). Although both diminutive and
enlarged fibers are also seen in Myo-CELFD-396 muscle
(Figure 3E), fiber size is more uniform in the lower-expressing
Myo-CELFD-396 line than in the Myo-CELFD-370 line, and the
overall variance in fiber sizes does not differ significantly from that
of wild type (P=0.36). No differences in the number of muscle
fibers were detected in Myo-CELFD mice (Figure S2).
Myo-CELFD transgenic mice exhibit changes in muscle
fiber subtype
Skeletal muscle is composed of two basic fiber types. Slow twitch
(Type I) fibers are aerobic, fire slowly, and are resistant to fatigue.
Fast twitch (Type II) fibers are often anaerobic, and both fire and
fatigue more quickly than slow twitch fibers. To determine
whether the fiber type composition is altered in Myo-CELFD
mice, sections of isolated soleus muscles from sex- and age-
matched wild type and Myo-CELFD mice were stained for
myofibrillar actomyosin ATPase under basic conditions. Using this
protocol, the Type I ATPase is alkaline labile, leaving slow twitch
fibers pale, while Type II ATPase is alkaline stabile, resulting in
dark staining of fast twitch fibers. The soleus muscle was chosen
for this analysis because it normally has a mixture of slow and fast
twitch fiber types in mice, so a shift towards either subtype would
be detectable. A small but significant shift from fast to slow twitch
fibers was observed in Myo-CELFD-370 mice (Figure 4). Although
the baseline percentage of fast twitch fibers changed in wild type
mice between 15 weeks and six months (Figure 4B), the percentage
of fast twitch fibers in Myo-CELFD-370 mice decreased
proportionally. A similar shift in the proportion of fast to slow
Figure 2. The alternative splicing of some transcripts is
affected in Myo-CELFD muscle. The alternative splicing of
transcripts that were previously identified as targets of CELF regulation
in the mouse heart was evaluated in the pectoral muscles of nonparous
female wild type and Myo-CELFD-370 siblings at 24 weeks. H2afy
mutually exclusive exons 6 and 7 (A) and Capzb exon 8 (B) exhibited
significant changes in splicing. (C) C10orf97 exon 5 showed a trend
towards decreased inclusion in pectoral muscle. Although not
statistically significant in pectoral muscle, a significant decrease in
exon inclusion was observed in thigh muscle (data not shown; see text).
(D) Nrap exon 12, which is repressed in DM1 skeletal muscle, displayed
a significant increase in inclusion in Myo-CELFD muscle. An asterisk
denotes a significant difference from wild type (P#0.05).
doi:10.1371/journal.pone.0019274.g002
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adult Myo-CELFD-396 littermates (data not shown).
Muscle performance is not affected in Myo-CELFD mice
ToassesswhethermusclestrengthisalteredinMyo-CELFDmice,
a longitudinal assessment of in vivo grip strength was conducted for
wild type and Myo-CELFD-370 mice. Fore- and hind limb grip
strengths were measured every four weeks over a time course from
eight to 24 weeks of age and normalized to body weight. No
significant differences were observed between sex- and age-matched
wild type and Myo-CELFD-370 mice in either fore- or hind limb
gripstrengthatanyagetested,indicating thatthereisnoovertlossor
gain of limb muscle strength in the transgenic mice (Figure 5).
Muscle performance was also assessed ex vivo. Force, fatigue, and
contraction and relaxation times were compared between isolated
extensor digitorum longus (EDL), soleus, and diaphragm muscles
from wild type and Myo-CELFD-370 mice. Values for force did
not differ at any stimulation frequency between wild type and
transgenic mice in any of the three muscles evaluated (Figure 6),
consistent with these mice exhibiting no differences in overall limb
muscle strength in vivo (Figure 5). Myo-CELFD-370 mice also
exhibited no differences in fatigue resistance relative to wild type
when any of the muscles were stimulated repetitively with 25 or
50 Hz train stimulation (Figure S3). Contraction time and half
relaxation times were calculated as measures of contractile
performance. The contraction time did not differ significantly in
Myo-CELFD-370 mice in any of the muscles evaluated with
stimulation at either 25 or 50 Hz (Figure S4). The half relaxation
time did not differ at either frequency in EDL or soleus, but was
significantly increased at some time points in diaphragm at 50 Hz
(Figure S5). Although significant differences were seen only in
parts of the stimulation train, an increase in the half relaxation
times are consistent with a shift towards more slow twitch fibers.
Taken together with the in vivo data, these ex vivo results indicate
that disruption of CELF-mediated alternative splicing in the
skeletal muscle by repression of CELF activity neither enhances
nor impedes muscle performance.
Discussion
Only some of the transcripts that were previously identified as
being targets of CELF-mediated alternative splicing regulation in
the heart [4,21] showed a demonstrable change in alternative
splicing in Myo-CELFD muscle (Figure 2 and Table 1). The
changes that were observed were generally mild, not exceeding
,12% change in the level of exon inclusion relative to the total
pool of transcripts. The mildness or lack of effect on alternative
splicing in Myo-CELFD mice may reflect a lesser regulatory role
for CELF proteins in skeletal muscle. Alternative splicing
outcomes are the result of combinatorial regulation of exon
recognition by multiple, sometimes antagonistic, factors that may
vary between tissues and developmental stages. CELF activity may
therefore be determinative for inclusion of an exon in heart, but
not in skeletal muscle. Consistent with this idea, alternative
splicing is far less disrupted in skeletal muscle in Myo-CELFD mice
than in the hearts of MHC-CELFD mice. For example, inclusion
of alternative exons in Itgb1 and Mef2A transcripts is significantly
reduced in the hearts of both MHC-CELFD lines [22], but
remains unaffected in Myo-CELFD-370 pectoralmuscles (Table 1).
NLSCELFD transcript levels in pectoral muscle of the Myo-
CELFD-370 line fall between levels measured in the hearts of the
higher-expressing MHC-CELFD-10 and lower-expressing MHC-
CELFD-574 lines (data not shown), so the lack of response in Myo-
CELFD muscle is likely not due to insufficient transgene
expression. It must be cautioned, however, that the level of
residual CELF activity in the presence of the NLSCELFD protein
cannot be directly measured, preventing a true comparison of the
extent of repression of CELF activity in Myo-CELFD versus
MHC-CELFD tissues. The possibility that NLSCELFD is less
effective at inhibiting CELF activity in skeletal muscle than in
heart muscle cells cannot be ruled out.
Other explanations for the weak or absent response of some
targets are possible. For example, the lack of effect on some
transcripts in Myo-CELFD muscle may simply reflect the
developmental timing of when CELF proteins act on these targets.
For example, in the heart Mfn2 exon 3 is partially skipped at
embryonic stages when CELF1 and CELF2 protein levels are
high, but is nearly 100% included in adult after CELF protein
expression has decreased [4]. Over-expression of CELF1 is
sufficient to recapitulate the embryonic splicing pattern of Mfn2
in the adult heart [4], but repression of CELF activity would not
be expected to have any effect if the levels of CELF proteins in
adult tissues are already below the threshold required to influence
splicing of this exon. Targets such as Itgb1 exon D and Mef2A
Table 1. Alternative splicing of unaffected CELF targets.
Alternative region Predicted effect on % inclusion in pectoral muscle (n)
c P value
inclusion Wild type Myo-CELFD
Ank2 exon 21
a Increase 89.360.6 (4) 90.261.3 (3) 0.31
Atp2b1 exon 21
a Increase 56.163.4 (4) 59.264.0 (3) 0.29
Mfn2 exon 3
a Increase 95.160.6 (3) 95.362.4 (3) 0.46
Ppfibp1 exon 4
a Increase 36.562.8 (4) 40.064.1 (3) 0.26
Sorbs1 exon 6
a Increase 58.061.3 (3) 55.061.9 (3) 0.14
Xpo7 exon 4 59ss
a Increase 50.361.4 (4) 51.460.9 (3) 0.25
Bin 1 exon 10
b Increase 98.260.3 (3) 98.560.2 (3) 0.19
Itgb1 exon D
b Decrease 49.763.4 (4) 49.763.1 (3) 0.50
Mef2A exon 16
b Decrease 85.961.5 (4) 88.161.7 (3) 0.20
aBased on the effect of over-expressing CELF1 in the heart (i.e. the opposite direction) [4].
bBased on the effect of repressing CELF activity in the heart (i.e. the same direction) [21].
cn= number of samples in group.
doi:10.1371/journal.pone.0019274.t001
CELF Activity Regulates Muscle Fiber Properties
PLoS ONE | www.plosone.org 5 April 2011 | Volume 6 | Issue 4 | e19274CELF Activity Regulates Muscle Fiber Properties
PLoS ONE | www.plosone.org 6 April 2011 | Volume 6 | Issue 4 | e19274exon 16, however, are affected by NLSCELFD-mediated repres-
sion of CELF activity in the heart even at 24 weeks of age [22].
This suggests they should remain responsive in adult skeletal
muscle, yet Myo-CELFD mice exhibit wild type splicing patterns
for these transcripts.
Whatever the reason, it is nonetheless striking that the modest
alternative splicing changes observed in Myo-CELFD mice were
sufficient to induce changes in muscle organization, fiber size, and
fiber subtype. Individual muscle fibers and muscle fascicles appear
more compacted in Myo-CELFD muscle (Figure 3A). Although
the functional consequences of reduced endomysial and perimysial
spacing is not clear, connective tissue in the perimysium has been
suggested to play a role in transmitting lateral contractile
movements [26]. The extent of interstitial spacing in muscle
appears to correlate with the level of CELF activity, as expansion
and fibrosis of the muscle interstitia are observed in mouse models
that over-express CELF1 in skeletal muscle [18,20]. Large
variations in muscle fiber size and an increase in the proportion
of slow twitch muscle are observed in both Myo-CELFD mice
(Figures 3B-F and 4) and mice over-expressing CELF1 [18,20].
These results indicate that either too much or too little CELF
activity will lead to the dysregulation of muscle fiber size and
muscle fiber subtype. Notably, all three of these salient features
affected in the Myo-CELFD phenotype – interstitial spacing, fiber
size variability, and fiber type composition – are features that are
affected in skeletal muscles from DM1 patients and mouse models
Figure 4. Fiber type composition is altered in Myo-CELFD mice.
(A) Representative sections of soleus muscles isolated from 15 week old
wild type and Myo-CELFD-370 littermates that have been stained for
myofibrillar actomyosin ATPase activity are shown. Pale fibers = slow
twitch (Type I), dark fibers = fast twitch (Type II). (B) The number of
slow twitch (pale) and fast twitch (dark) fibers were counted in 15 week
old or 6–12 month old wild type and Myo-CELFD-370 littermates and
mean values were calculated for each group. An asterisk denotes a
significant difference from wild type (P#0.05).
doi:10.1371/journal.pone.0019274.g004
Figure 5. Grip strength is unaffected in Myo-CELFD mice.
Forelimb (A) and hind limb (B) grip strengths were measured every four
weeks in a cohort of wild type and Myo-CELFD-370 siblings over a
sixteen week time course. Force measurements were normalized
against body weight. Males and females were assessed independently
due to sex differences in muscle mass and body weight. No significant
differences were found between sex-matched wild type and transgenic
mice at any age evaluated.
doi:10.1371/journal.pone.0019274.g005
Figure 3. Myo-CELFD mice have altered skeletal muscle organization and variable muscle fiber size. (A) Transverse cross-sections of the
lower forelimb of adult Myo-CELFD-370 mice reveal a reduction in the endomysial and perimysial spaces relative to that of a wild type littermate.
Sections shown are representative of three independently processed sex- and age-matched littermate pairs. Higher magnification views of muscles
from wild type (B) and Myo-CELFD-370 (C) littermates or wild type (D) and Myo-CELFD-396 (E) littermates reveal an increased prevalence of both
enlarged (arrows) and diminutive (arrowheads) muscle fibers in transgenic mice. In order to ensure that the same muscle groups are being compared
between wild type and transgenic mice, the regions shown in (B) and (C) are from a portion of the cross-section where the reduction in spacing
around the muscle fibers in the Myo-CELFD-370 limb was less pronounced. (F) Fiber area was measured for muscle fibers within matched regions of
hind limb sections from two sex- and age-matched MyoCELFD-370 and wild type pairs. Fiber size varied more in transgenic muscles, with an
enrichment of both smaller (arrowheads) and larger (arrows) fibers relative to wild type muscles.
doi:10.1371/journal.pone.0019274.g003
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addition to up-regulation of CELF1, sequestration and subsequent
loss of function of muscleblind-like 1 (MBNL1) has been
implicated in DM1 pathogenesis [30]. Notably, however, none
of these features have been reported in MBNL1 knockout mice,
which do exhibit other hallmarks of the disease such as centralized
nuclei and split fibers [31]. Together, these results suggest that
inappropriate CELF-mediated alternative splicing regulation may
be largely responsible for these characteristics of DM1 muscle.
Roles for CELF proteins in normal skeletal muscle organization
and composition have been suggested by previous studies in other
animal models. The full complement of CELF family members
arose from paralogous gene duplications in vertebrates, so
invertebrate species possess only a single ortholog of CELF1/
CELF2 [32]. RNAi-mediated inactivation of etr-1, the Caenorhab-
ditis elegans homolog of CELF1/CELF2, causes embryonic
lethality, accompanied by defects in muscle assembly, contractility,
and attachment [33]. In vertebrates, repression of the Xenopus
ortholog of CELF1 by either antisense knockdown or neutralizing
antibodies in early frog embryos leads to defects in segmentation of
the somites, which give rise to skeletal muscle [34]. In both C.
elegans and Xenopus, early loss of CELF activity led to disorgani-
zation of muscle, but not perturbation of muscle differentiation per
se. These results are consistent with our data that suggest that
CELF activity is required for muscle organization, but not overall
muscle mass. CELF1 knockout mice exhibit growth retardation,
but a specific muscle phenotype has not been reported [35]. Early
placentation defects in these mice may make it difficult to
distinguish between specific changes in muscle mass and a general
failure to thrive. CELF2 null mice have not yet been reported. In
each of the worm, frog, and mouse knockdown/knockout models,
the phenotype is more severe than that of the Myo-CELFD mice,
which appear overtly healthy. This may be due to the difference
between modulating total CELF protein levels and specific
repression of CELF splicing activity. Both CELF1 and CELF2
are expressed in the cytoplasm as well as the nucleus in heart and
skeletal muscle [4,6,36], and have been implicated in the
regulation of cytoplasmic processes as well. For example, loss of
CELF1 in Xenopus embryos has been shown to impair dead-
enylation [37,38], and CELF1 has been implicated in translational
regulation during muscle maturation in mice [39]. Therefore the
contributions of disrupted cytoplasmic CELF activity and
disrupted CELF-mediated alternative splicing to the phenotype
may be difficult to separate in these models. Although the
possibility of indirect effects on the cytoplasmic functions of
CELF1 and CELF2 cannot be absolutely eliminated, the
restriction of the dominant negative protein to the nucleus means
the Myo-CELFD phenotype can most likely be attributed directly
to changes in CELF-mediated alternative splicing.
Materials and Methods
Ethics statement
This study was conducted in strict accordance with the
recommendations of the American Veterinary Medical Associa-
tion and under the approval of the Institutional Animal Care and
Use Committees of the Cleveland Clinic (Protocol numbers: ARC
07926 and ARC 08612) and Cleveland Veterans Affairs Medical
Center (Protocol number: 06-15-EvL-MS1). All efforts were made
to minimize pain and distress during animal husbandry,
experimental assessments, and euthanasia.
Generation of Myo-CELFD mice
The nuclear-restricted dominant negative CELF protein,
NLSCELFD, was previously described [21]. The skeletal muscle-
specific dominant negative transgene, Myo-CELFD, was created
by subcloning the NLSCELFD open reading frame downstream of
mouse myogenin 59 flanking genomic sequence (provided by
William Klein, University of Texas M.D. Anderson Cancer
Center, Houston, TX) containing an ,1.5 kb myogenin promot-
er, first intron, and 59 end of exon 2, but in which the myogenin
exon 1 was replaced by an exon from the 59 untranslated region of
b-globin; this promoter construct drives efficient expression of a
green fluorescent protein reporter in mouse C2C12 myoblast cells
that have been differentiated into myotubes following transient
transfection (data not shown). The 39 untranslated region of
bovine growth hormone was amplified from the pcDNA3.1+
vector (Invitrogen) and subcloned downstream of the NLSCELFD
open reading frame. The expression cassette was excised with
XhoI and XbaI and microinjected into the pronuclei of fertilized
Figure 6. Force measurements are not affected in skeletal
muscles from Myo-CELFD mice. Force was assessed ex vivo in
extensor digitorum longus (EDL) (A), soleus (B), and diaphragm (C)
muscles isolated from sex- and age-matched wild type and Myo-CELFD-
370 mice. No significant differences were found at any frequency.
doi:10.1371/journal.pone.0019274.g006
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Facility (Case Western Reserve University, Cleveland, OH).
Genotyping was performed by PCR amplification of mouse tails
lysed in DirectPCR Lysis Reagent (Viagen Biotech, Inc.). A
410 bp Myo-CELFD transgene product (primers CCTAGAAGC-
TAGGAAAGACC and GTGGGAGGAGTACTTCACAAAG)
and a 550 bp actin internal control product (primers GATGT-
GCTCCAGGCTAAAGTT and AGAAACGGAATGTTGTG-
GAGT) were amplified in the same reaction using an annealing
temperature of 55uC and 30 cycles of amplification and resolved
by agarose gel electrophoresis.
Western blot analysis
Muscle tissue was homogenized inprotein loadingbuffer (0.64 M
Tris HCl, pH 6.8, 10% glycerol, 2% SDS, 5% b-mercaptoethanol),
total protein samples were quantitated, resolved by polyacrylamide
gel electrophoresis, transferred, and probed as previously described
[5] using a monoclonal antibody against the N-terminal poly-
histidine region or Xpress epitope tag (Invitrogen). Equivalent
loading was confirmed by Ponceau S staining.
Semi-quantitative RT-PCR
RT-PCR was performed as previously described [21], using
conditions optimized for each primer set for amplification in the
linear range with 250 ng total RNA: NLSCELFD primers
GTATGGCTAGCATGACTGGTG and GCGTGGGAGGAG-
TACTTCAC, 62uC annealing temperature, and 24 cycles of
amplification; 18S primers GGTAACCCGTTGAACCCCATTC
and GGACCTCACTAAACCATCCAATCG, 56.7uC annealing
temperature, and 8 cycles of amplification. Samples being
compared were run in parallel with both primer sets, and
NLSCELFD levels were normalized against 18S levels.
Alternative splicing
Total RNA was extracted from hearts of transgenic and wild
type littermates and subjected to single-tube RT-PCR analysis as
previously described [21]. Mef2A, Itgb1, and Bin1 primers and
PCR conditions are the same as used for MHC-CELFD mice [21].
Additional primer sets and reaction conditions are taken from
Kalsotra and colleagues [4], with the exception of those for Nrap
exon 12, which are from Lin and colleagues [25].
Histology and fiber type analysis
Limbs of wild type and transgenic sex-matched littermates were
transected and fixed overnight by immersion in 10% neutrally
buffered formalin, embedded in paraffin, sectioned, and stained
with hematoxilin and eosin. Interstitial area and fiber area were
quantified using ImagePro Plus software (Media Cybernetics). For
fiber type analysis, mice were anesthetized with an intraperitoneal
injection of rodent anesthetic cocktail (ketamine, xylazine, and
acepromazine), soleus muscles were surgically removed, embedded
in tragacanth, rapidly frozen in isopentane cooled with liquid
nitrogen, and sectioned on a cryostat. Sections were preincubated
at room temperature in alkaline stock solution (75 mM glycine,
50 mM CaCl2, and 75 mM NaCl, pH 9.4) adjusted to pH 10.3
with NaOH for 15 min and rinsed three times with distilled water.
Sections were then incubated in ATP solution (2.5 mM ATP in
alkaline stock solution, pH 9.4) for 45 min at 37uC, and rinsed
three times with distilled water. Sections were then serially
incubated in 1% CaCl2 for 3 min, 2% CoCl2 for 3 min, and
1% NH4SH for 1 min, rinsing three times with distilled water after
each. Sections were allowed to air dry and were mounted in
Permount (Fisher Scientific). The number of dark and light fibers
were counted using ImagePro Plus software. The samples sizes
that are indicated are the number of individual mice in each
group; replicate sections were independently stained and counted
for each individual to ensure that observed differences are not due
to variability in stain intensity between slides.
In vivo grip strength assessments
Grip strength tests were performed in the Lerner Research
Institute Rodent Behavioral Core using a digital grip strength
meter (Columbus Instruments, Columbus, OH). To measure
forelimb grip strength, each mouse was gently pulled away from
the meter in a horizontal plane after it had gripped the bar, and
the force applied to the bar immediately before the mouse
released its grip was recorded. To measure hind limb grip
strength, each mouse faced away from the meter with its
forelimbs resting on the investigator’s hand, and was pulled gently
toward the meter in a horizontal plane. All mice underwent a
training session the day prior to each session in which
measurements were recorded. Animals completed 10 consecutive
trials per session, and the measurements were averaged. Total
body weight was measured at the end of each session. Grip
strength measurements were made on the same individuals over a
time course of 4, 8, 12, 16, 20, and 24 weeks of age and values
were normalized to body weight.
Ex vivo isometric muscle force and contractility
measurements
For ex vivo isometric contractility assessments, mice were
anesthetized and the diaphragm, EDL, and soleus muscles along
with their tendons were surgically removed and kept in an
aerated bath of physiological Krebs solution. The diaphragm was
cut into strips, while the EDL and soleus were left intact. Each
muscle or muscle strip was mounted vertically in a double-
jacketed bath of aerated (95% O2/5% CO2)p h y s i o l o g i c a l
solution (135 mM NaCl, 5 mM KCl, 2.5 mM CaCl2,1 m M
MgSO4, 1 mM NaH2PO4,1 5 m MN a H C O 3,a n d1 1 m M
glucose, pH adjusted to 7.35–7.45) at 37uC. Supramaximal
voltages with a pulse width of 1 ms were delivered to muscles by a
pair of platinum electrodes placed in parallel. The length of each
muscle was adjusted to maximize twitch force. Following
equilibration of the muscle, several baseline twitches were
recorded. Muscles were subjected to an intermittent stimulation
protocol in which a 333 ms stimulus train per minute was
administered over a range of 1 to 120 Hz. Intermittent fatigue
stimulation was used to test fatigue resistance for 300 sec at a
frequency of either 25 or 50 Hz for a 333 ms train every second.
Contractile performance was assessed by measuring peak force,
contraction time (the time from the onset of force production to
the top of the first peak of contraction), and half relaxation time
(the time required for force to decrease 50% from the peak value
at the end of stimulation).
Statistics
Data are reported as mean 6 standard error of the mean unless
otherwise noted.
Contractility data were analyzed with repeated measures of
analysis of variance followed by the Newman-Keuls test in the
event of significance by analysis of variance. Comparisons
between means for other data were performed via t-test assuming
unequal variances using Microsoft Excel software. Comparisons
of variances were performed via f-test using Microsoft Excel
software. Differences were considered statistically significant
when P#0.05.
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Figure S1 Myo-CELFD transgenic mice exhibit normal
body weight. Body weights of Myo-CELFD-370 and wild type
littermates from several litters were measured over a time course of
8, 12, 16, 20, and 24 weeks, and means for each group were
determined. Males and females were assessed independently due
to sexual dimorphism. Mean Myo-CELFD-370 body weights did
not significantly differ from those of sex-matched wild type mice at
any age.
(TIF)
Figure S2 Muscle fiber number is not affected in Myo-
CELFD mice. Muscle fibers were counted in regions of
transverse cross-sections of hind limbs using ImagePro Plus
software (Media Cybernetics). Three different muscle groups were
counted in each of two sex- and age-matched Myo-CELFD-370
and wild type littermate pairs, and mean values for each muscle
group were compared. Muscle groups were chosen from regions
where interstitial spaces were sufficiently evident in the Myo-
CELFD-370 sections to allow for unambiguous identification of
the corresponding muscle group in wild type sections.
(TIF)
Figure S3 Muscle fatigue is not affected in skeletal
muscles from Myo-CELFD mice. Fatigue was assessed ex vivo
by intermittent fatigue stimulation at 25 or 50 Hz in extensor
digitorum longus (EDL) (A), soleus (B), and diaphragm (C) muscles
isolated from sex- and age-matched wild type and Myo-CELFD-
370 mice. No significant differences were found.
(TIF)
Figure S4 Contraction time is not affected in skeletal
muscles from Myo-CELFD mice. The time from the onset of
force production to the top of the first peak of contraction was
measured ex vivo in EDL (A), soleus (B), and diaphragm (C) muscles
isolated from sex- and age-matched wild type and Myo-CELFD-
370 mice at 25 and 50 Hz. No significant differences were found.
(TIF)
Figure S5 Half relaxation time is largely unaffected in
skeletal muscles from Myo-CELFD mice. The half
relaxation time, calculated as the time required for force to
decrease 50% from the peak value at the end of stimulation, was
measured ex vivo in EDL (A), soleus (B), and diaphragm (C) muscles
isolated from sex- and age-matched wild type and Myo-CELFD-
370 mice at 25 and 50 Hz. No significant differences were found
for EDL or soleus. A small but significant increase in half
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